April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Eplerenone use to treat Central Serous Chorioretinopathy
Author Affiliations & Notes
  • Javier Moreno
    Grupo VISTA Gutiérrez Amorós, La Coruña, Spain
  • Footnotes
    Commercial Relationships Javier Moreno, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1926. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Javier Moreno; Eplerenone use to treat Central Serous Chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1926.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Based on experimental data showing that Central Serous Chorioretinopathy (CSC) could result from overactivation of mineralocorticoid receptor pathway in choroid vessels, eplerenone, a mineralocorticoid receptor antagonist, was studied as a potential treatment for CSC.

Methods: Three patients diagnosed of unilateral CSC were treated with eplerenone 25 mgrs/day. All three patients did not received any previous treatment, all of them had an onset of symptoms for more than three months. Prior to treatment, Visual Acuity (VA) was taken (Snellen chart), Optical Coherence Tomography (OCT, Cirrus Humphrey-Zeiss) of the macular area, was performed also, evaluating the height of the subretinal fluid at the fovea, and the total volumen at the macular cube. The evaluation was repeated at one month, two months and three months after treatment.

Results: There was an improve in VA in all three patients since the first month after initiating treatment and it was related with a decrease in the subretinal fluid, measured with OCT, with less height at the subfoveal space and a decrease in total volume measured through macular cube.

Conclusions: Eplerenone seems to be an alternative to treat CSC with good results. It could be interesting to prove this treatment in a ramdomized controlled trial with more cases.

Keywords: 452 choroid • 688 retina  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.